Antimicrobial Wound Gel Manufacturing and Formulation

The contract pertains to the full-scale manufacturing of an antimicrobial wound gel, requiring precise biochemical formulation, rigorous batch testing, and comprehensive quality assurance to ensure compliance with established shelf-life durability and therapeutic performance benchmarks. The work involves end-to-end production processes that guarantee consistency, sterility, and efficacy in line with medical standards, with all outcomes subject to stringent validation protocols. Production is to be performed at Cannon AFB, New Mexico, 88101-5009, under a subcontract arrangement issued by the Department of Defense through the Medical Supply Chain MD SURG FSF. The opportunity was posted on April 30, 2026, with a response deadline of May 6, 2026, and is classified under NAICS code 325412 for pharmaceutical and medicinal manufacturing. All deliverables must meet or exceed technical specifications for stability, antimicrobial activity, and safety to support military medical readiness, with no set-aside provisions specified.